A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

导出 LinkOut

翻译打印收藏纠错

作者： Sten,Fredrikson ^[1] ; Euan,McLeod ; Nathaniel,Henry ; Ashley,Pitcher ; Julia,Lowin ; Matthieu,Cuche ; Liberty,Fajutrao ; Rodolphe,Perard ; David,Bates ; Andrew,Chan

作者单位： Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. ^[1]

主题词佐剂, 免疫(Adjuvants, Immunologic);费用效益分析(Cost-Benefit Analysis);脱髓鞘疾病(Demyelinating Diseases);人类(Humans);输注, 皮下(Infusions, Subcutaneous);干扰素β(Interferon-beta);伊曲康唑(Itraconazole);Markov链(Markov Chains);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);瑞典(Sweden);治疗结果(Treatment Outcome)

DOI 10.3111/13696998.2013.792824

PMID 23556422

发布时间 2015-11-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览16

Journal of medical economics

2013年16卷6期

756-62页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

检索历史清除